Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker MDGL · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Resmetirom in Patients With MASH and HFpEF NCT07830758 · MASH - Metabolic Dysfunction-Associated Steatohepatitis, He… Resmetirom, Placebo | MDGL Madrigal Pharmaceuticals, Inc. | Phase 1 | Recruiting | 90 | Nov 2027 | Registry ↗ |
| Oct 16, 2026 | Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and… NCT07848191 · MASH - Metabolic Dysfunction-Associated Steatohepatitis Rezdiffra, Resmetirom | MDGL Madrigal Pharmaceuticals, Inc. | Phase 4 | Recruiting | 150 | Nov 2027 | Registry ↗ |
| Sep 11, 2026 | Study of Resmetirom in Children and Adolescents With MASH NCT07763015 · MASH, MASH - Metabolic Dysfunction-Associated Steatohepatit… Resmetirom | MDGL Madrigal Pharmaceuticals, Inc. | Phase 2 | Recruiting | 61 | Jul 2029 | Registry ↗ |
| Aug 26, 2026 | Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH NCT07335601 · MASH - Metabolic Dysfunction-Associated Steatohepatitis Resmetirom, Placebo | MDGL Madrigal Pharmaceuticals, Inc. | Phase 2 | Recruiting | 120 | Aug 2028 | Registry ↗ |
| Jul 8, 2026 | A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-com… NCT05500222 · NASH, Cirrhosis, Liver Resmetirom, Placebo | MDGL Madrigal Pharmaceuticals, Inc. | Phase 3 | Active, not recruiting | 845 | Dec 2026 | Registry ↗ |
| Jun 4, 2026 | Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) NCT03038022 · Heterozygous Familial Hypercholesterolemia MGL-3196 (resmetirom), Placebo | MDGL Madrigal Pharmaceuticals, Inc. | Phase 2 | Completed | 116 | Jan 15, 2018 | Registry ↗ |
| Jun 1, 2026 | A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH… NCT03900429 · NASH - Nonalcoholic Steatohepatitis MGL-3196, Placebo | MDGL Madrigal Pharmaceuticals, Inc. | Phase 3 | Active, not recruiting | 1,759 | Jan 2028 | Registry ↗ |
| May 27, 2026 | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alc… NCT04951219 · Non-Alcoholic Fatty Liver Disease Resmetirom | MDGL Madrigal Pharmaceuticals, Inc. | Phase 3 | Active, not recruiting | 810 | Mar 2027 | Registry ↗ |
| Apr 21, 2026 | Rezdiffra Pregnancy and Lactation Registry NCT07541469 · MASH - Metabolic Dysfunction-Associated Steatohepatitis Rezdiffra | MDGL Madrigal Pharmaceuticals, Inc. | — | Recruiting | 10 | Apr 8, 2030 | Registry ↗ |
| Dec 23, 2025 | Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) NCT02912260 · Non-alcoholic Steatohepatitis MGL-3196, Placebo | MDGL Madrigal Pharmaceuticals, Inc. | Phase 2 | Completed | 125 | Oct 25, 2017 | Registry ↗ |
| Oct 14, 2025 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days)… NCT06397872 · Renal Impairment 100 mg Resmetirom Tablet | MDGL Madrigal Pharmaceuticals, Inc. | Phase 1 | Completed | 28 | Sep 16, 2024 | Registry ↗ |
| Oct 5, 2023 | Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of… NCT04643795 · Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis MGL-3196 | MDGL Madrigal Pharmaceuticals, Inc. | Phase 1 | Completed | 87 | Aug 4, 2021 | Registry ↗ |
| Sep 5, 2023 | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty L… NCT04197479 · Non-Alcoholic Fatty Liver Disease Placebo, Resmetirom | MDGL Madrigal Pharmaceuticals, Inc. | Phase 3 | Completed | 1,343 | Jan 6, 2023 | Registry ↗ |
| Aug 22, 2023 | Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects NCT01367873 · Drug Safety Placebo, VIA-3196 | MDGL Madrigal Pharmaceuticals, Inc. | Phase 1 | Completed | 72 | Oct 2011 | Registry ↗ |
| Sep 2, 2022 | Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin NCT02542969 · Healthy Simvastatin, Rosuvastatin | MDGL Madrigal Pharmaceuticals, Inc. | Phase 1 | Completed | 25 | Oct 2015 | Registry ↗ |
| Dec 28, 2020 | Drug Interaction Study of MGL-3196 With Clopidogrel NCT04671069 · Healthy MGL-3196, Clopidogrel | MDGL Madrigal Pharmaceuticals, Inc. | Phase 1 | Completed | 20 | Aug 30, 2019 | Registry ↗ |
| Dec 17, 2020 | Drug Interaction Study of MGL-3196 With Pioglitazone NCT04671056 · Healthy MGL-3196, Pioglitazone 15mg | MDGL Madrigal Pharmaceuticals, Inc. | Phase 1 | Completed | 16 | Dec 11, 2018 | Registry ↗ |
| Sep 18, 2019 | Bioavailability Study of MGL-3196 Tablets Compared to Capsules NCT03413124 · Healthy MGL-3196 Tablet, MGL-3196 Capsule | MDGL Madrigal Pharmaceuticals, Inc. | Phase 1 | Completed | 16 | Feb 17, 2018 | Registry ↗ |
| Dec 19, 2017 | Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196 NCT03220165 · Healthy MGL-3196 | MDGL Madrigal Pharmaceuticals, Inc. | Phase 1 | Completed | 8 | Sep 3, 2017 | Registry ↗ |
| Aug 30, 2016 | Drug Interaction Study of MGL-3196 With Atorvastatin NCT02749578 · Healthy Atorvastatin, MGL-3196 | MDGL Madrigal Pharmaceuticals, Inc. | Phase 1 | Completed | 14 | May 2016 | Registry ↗ |
20 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:36 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances